#Vienna #Austria #Longevous Beamtech #LB-30 #EANM

Longevous Beamtech Introduces the LB-30 Series at EANM 2026

In a significant development for the medical technology sector, Longevous Beamtech (LBT) introduced its latest LB-30 series 30 MeV medical cyclotron platform at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 2026) held in Vienna, Austria, from October 17 to 21, 2026. This unveiling marks a pivotal moment not only for LBT but also for the entire radiopharmaceutical community, as it greatly expands the potentials for radionuclide production and research.

Extending Radionuclide Production Capabilities

As the landscape of radiopharmaceuticals evolves, so too does the demand for a broader spectrum of radionuclides. Traditionally, the focus was on established PET isotopes commonly utilized in clinical settings. However, today's research institutions and radiopharmaceutical companies are exploring an enlarged array of radionuclides, aimed at diverse applications, including diagnostic imaging, therapeutic treatments, and experimental studies. The LB-30 cyclotron has been meticulously engineered to cater to these shifting demands for radionuclide production, featuring distinct capabilities.

Highlights of the LB-30 series include compatibility with various particle types, continuous variable energy beam extraction, and high-efficiency beam transport. It is equipped with clean vacuum technology alongside flexible target station solutions. Such a configuration allows for unparalleled adaptability in selecting particle types, tailoring beam energy, and configuring targets to meet diverse irradiation needs.

With these advancements, the LB-30 cyclotron supports a wider range of radionuclide production pathways and applications within the research environment. Furthermore, the new platform signifies a monumental step for LBT, transitioning their existing cyclotron systems—which are primarily utilized for routine clinical isotopes—into the arena of high-energy, multipurpose isotopes.

Integrated Production Solutions

In addition to innovative cyclotron technology, LBT has focused on a holistic approach to radionuclide production. Their comprehensive portfolio encompasses target systems, radiopharmaceutical synthesis solutions, distribution mechanisms, hot cells, quality control schemes, and a wide array of engineering services. This broad spectrum ensures facilities can be optimally configured to meet specific isotope requirements, production volumes, exploratory research objectives, and developmental aspirations for the future.

This integrated strategy is profoundly beneficial to hospitals, radiopharmaceutical manufacturers, and research institutes, as it provides a tailored production framework featuring advanced solutions for current and future needs.

LB-30’s Grand Debut at EANM 2026

During the EANM 2026 event, the LB-30 was brought to the forefront among nuclear medicine professionals, radiopharmaceutical enterprises, researchers, and international industry partners. Engaging discussions centered on advances in radionuclide production, innovative radiopharmaceuticals, and the evolving technological demands of future production facilities. This platform afforded LBT the invaluable opportunity to interact directly with experts across the nuclear medicine sector.

As the LB-30 makes its official entrance into the market, it fundamentally enriches LBT’s array of medical cyclotrons, enhancing the company's capabilities in versatile high-energy radionuclide production and radiopharmaceutical research. LBT's commitment to innovation in this field is clear, as they prepare to meet both current and future challenges in radionuclide production.

For more information on the LB-30 and its capabilities, please contact LBT directly.